Table 1.
Performance of Alere™, Sofia® and BinaxNOW® influenza A and B assays.
| Alere™ Inf A&B | TP | FP | TN | FN | Total | % Sensitivity (95% CI) | % Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | |
|---|---|---|---|---|---|---|---|---|---|---|
| Study period 1 | 21 | 1 | 183 | 6 | 211 | 77.8 (57.7− 91.3) | 99.5 (97.0−99.9) | 95.5 (77.1 −99.2) | 96.8 (93.2 −98.8) | 0.84 |
| Study period 2 | 30 | 0 | 190 | 5 | 225 | 85.7 (69.7−95.1) | 100 (98.1−100) | 100 (88.3−100) | 97.4 (94.3− 99.2) | 0.91 |
| Study period 1 + 2 | 51 | 1 | 373 | 11 | 436 | 82.3 (70.5−90.8) | 99.7 (98.5− 100) | 98.1 (89.7 - 99.7) | 97.1 (94.3−98.6) | 0.88 |
| Sofia® Inf A + B | ||||||||||
| Study period 1 | 16 | 2 | 182 | 11 | 211 | 59.3 (38.8−77.6) | 98.9 (96.1−99.8) | 88.9 (65.2 −98.3) | 94.3 (90.0−97.1) | 0.68 |
| BinaxNOW® Inf A&B | ||||||||||
| Study period 1 | 8 | 0 | 183 | 19 | 210 | 29.6 (13.8−50.2) | 100 (98.0−100) | 100 (62.9−100) | 90.6 (85.7−94.2) | 0.42 |
TP: True positives; FP: False positives; TN: True negatives; FN: False negatives; PPV: Positive predictive value; NPV: Negative predictive value; CI: Confidence interval; : Interobserver agreement; Study period 1: February 2014–May 2014, Study period 2: December 2014–February 2015; data for influenza-A and -B were taken into account.